omeprazole has been researched along with Hand-Foot Syndrome in 1 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Hand-Foot Syndrome: Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine." | 8.02 | Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. ( Hiromoto, S; Inoue, M; Kawashiri, T; Kobayashi, D; Mine, K; Shimazoe, T; Uchida, M; Yamanaka, N, 2021) |
| "Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine." | 4.02 | Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. ( Hiromoto, S; Inoue, M; Kawashiri, T; Kobayashi, D; Mine, K; Shimazoe, T; Uchida, M; Yamanaka, N, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiromoto, S | 1 |
| Kawashiri, T | 1 |
| Yamanaka, N | 1 |
| Kobayashi, D | 1 |
| Mine, K | 1 |
| Inoue, M | 1 |
| Uchida, M | 1 |
| Shimazoe, T | 1 |
1 other study available for omeprazole and Hand-Foot Syndrome
| Article | Year |
|---|---|
Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome.
Topics: Animals; Capecitabine; Disease Models, Animal; Hand-Foot Syndrome; Mice; Mice, Inbred ICR; Omeprazol | 2021 |